News | June 19, 2009

ASTRO to Honor Drs. Lawrence, Shipley with Gold Medal at November Meeting

Theodore Lawrence, M.D., Ph.D., FASTRO

William Shipley, M.D., FASTRO

June 19, 2009 - The American Society for Radiation Oncology (ASTRO) has selected Theodore Lawrence, M.D., Ph.D., FASTRO, and William Shipley, M.D., FASTRO, as its 2009 Gold Medal recipients, the highest honor that ASTRO bestows. Dr. Lawrence and Dr. Shipley will be presented with their awards at the Gold Medal Ceremony being held November 3, 2009, at 10:45 a.m. during ASTRO's 51st Annual Meeting in Chicago.

"Dr. Lawrence and Dr. Shipley have been outstanding contributors to the Society and to the field of radiation oncology as a whole," said Patricia Eifel, M.D., FASTRO, ASTRO chairman. "It is an honor and a personal pleasure for me to be able to present them with the Gold Medal this year in recognition of their distinguished careers and dedication to the specialty."

Dr. Lawrence is an Isadore Lampe professor of radiation oncology, chair of the Department of Radiation Oncology and a professor in the Department of Environmental Health, School of Public Health at the University of Michigan in Ann Arbor, Mich.

On a national level, Dr. Lawrence is the chair of the National Cancer Institute Board of Scientific Councilors and a member of the Institute of Medicine. He is also the editor of Translational Oncology, an editor of The Cancer Journal: Journal of the Principles and Practice of Oncology, and the associate editor of Seminars in Radiation Oncology. Dr. Lawrence is an ASTRO past president and former chairman of the Board, and a past member of the ASCO board of directors. He was also named by the ASTRO Board of Directors as one of the first general co-chairs of the of the Radiation Oncology Institute's Vision of Value fundraising campaign, which will raise money to help develop innovative ways of enhancing the profile of radiation oncology in the world cancer community and prepare the specialty for the future. His interests in the laboratory are focused on chemotherapeutic and molecularly targeted radiosensitizers, and his clinical research combines these laboratory studies with conformal radiation guided by metabolic and functional imaging for the treatment of patients with gastrointestinal and central nervous system malignancies.

Dr. Shipley is chair of the genitourinary oncology unit at Massachusetts General Hospital and the Andres Soriano professor of radiation oncology at Harvard Medical School, both in Boston.

Dr. Shipley is very active in medical societies both in the United States and abroad and has held committee appointments with several of these organizations, including the International Congress of Radiation Oncology, the International Society of Radiation Oncology, the National Bladder Cancer Group and the Radiation Therapy Oncology Group, among many others. Dr. Shipley has authored and co-authored over 160 medical reports, three text books on genitourinary oncology and more than 140 book chapters. He was named a fellow of the American College of Radiology in 1988 and an ASTRO Fellow in 2006.

Dr. Shipley has been actively involved with ASTRO's International Education Subcommittee since 2003, and in 2006, organized the first ASTRO-led international scientific and educational meeting in the Philippines, which was designed to help strengthen ASTRO's involvement in radiation oncology abroad and collaborate with related specialty societies in other countries. ASTRO is the largest radiation oncology society in the world, with more than 10,000 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, biology and physics, the Society is dedicated to improving patient care through education, clinical practice, advancement of science and advocacy.

For more information: www.astro.org

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
Overlay Init